Silexion amends 8-K, delays Nasdaq transfer; reverse split expected in August to cure bid price deficiency

Silexion Therapeutics Corp

Nasdaq transfer to Capital Market not on July 8 as originally reported; now expected as soon as practicable.
Shareholder vote on 1-for-15 reverse split reconvenes July 14, 2025 at annual meeting.
After approval, 10-day Nasdaq notice period ends ~July 25; then 10 consecutive trading days above $1.00 needed.
Compliance with minimum bid price rule expected early to mid-August; no assurance of success.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.